During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
He has over 23 years of experience across sectors
_256_384.jpg)
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Branded formulation business continues to perform well across domestic and export markets
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Cancer cases in India estimated to reach 1.57 million in 2025
The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
Subscribe To Our Newsletter & Stay Updated
